HD-OPM Archive
Topics › Insulin resistance & diabetes

SGLT2 inhibitors cut fat mass about 7 lb without reducing fat-free mass in meta-analysis

Louis Nervegna · Jun 01, 2026 · ♥ 4 reactions · 3 comments · original Facebook post
Insulin resistance & diabetesWeight, visceral & liver fat
AI summary & key facts

Karl Nadolsky shares a systematic review and meta-analysis of randomized trials in Endocrine Practice. SGLT2 inhibitors modestly reduced fat mass while preserving fat-free mass, suggesting no muscle loss penalty.

SGLT2 inhibitors (like Jardiance) modestly reduce fat mass while preserving muscle.

On average, patients lost a little over 7lbs compared to controls, with no reduction in fat-free mass.

These results are from a recent meta-analysis and systematic review of randomized trials.

Link to journal paper:

endocrinepractice.orgLink to endocrinepractice.orgendocrinepractice.org

#sglt2HD #weightlossHD #muscleHD

Research cited

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been approved and widely used in patients with type 2 #diabetes with profound heart and kidney benefits. They essentially trick your kidneys into losing sugar into the urine, thus also losing calories with #WeightLoss.

This systematic review and meta-analysis randomized controlled trials evaluated the long-term effects of SGLT2 inhibitors on body composition, focusing on fat mass and fat-free mass.

Results: Compared with control groups, SGLT2 inhibitors significantly reduced fat mass while preserving fat-free mass. These findings suggest a potential protective effect on muscle and other lean components

PMID: 41419185

No photo description available.No photo description available.
← newer: High LDL is the largest modifiable dementia risk factor, tieolder: Healthier thymus on CT linked to 63% lower cardiovascular de →